Ropes Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Ropes Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40	Closed	-$1K	–	534
2018 Q3	$1K	Hold	40	–	–	﹤0.01%	517
2018 Q2	$1K	Hold	40	–	–	﹤0.01%	555
2018 Q1	$1K	Hold	40	–	–	﹤0.01%	571
2017 Q4	$1K	Hold	40	–	–	﹤0.01%	767
2017 Q3	$1K	Hold	40	–	–	﹤0.01%	697
2017 Q2	$1K	Sell	40 -130	-76%	-$4.02K	﹤0.01%	508
2017 Q1	$5K	Hold	170	–	–	﹤0.01%	472
2016 Q4	$6K	Sell	170 -250	-60%	-$9.98K	﹤0.01%	463
2016 Q3	$19K	Hold	420	–	–	0.01%	367
2016 Q2	$21K	Sell	420 -525	-56%	-$27.9K	0.01%	326
2016 Q1	$51K	Buy	945 +389	+70%	+$22.8K	0.02%	216
2015 Q4	$36K	Sell	556 -10	-2%	-$618	0.02%	265
2015 Q3	$32K	Buy	566 +21	+4%	+$1.36K	0.02%	290
2015 Q2	$32K	Hold	545	–	–	0.02%	212
2015 Q1	$34K	Buy	+545	New	+$31.7K	0.02%	210

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Ropes Wealth Advisors's TEVA Position: Q4 2018 in Review

Ropes Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 40 shares — an estimated $1K sold.

Ropes Wealth Advisors first reported a position in TEVA in Q1 2015 and held it in 15 quarters. The position peaked at $51K in Q1 2016. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Ropes Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ropes Wealth Advisors sold 40 Teva Pharmaceuticals shares in Q4 2018, an estimated $1K.
Ropes Wealth Advisors first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 15 quarters.
Ropes Wealth Advisors's Teva Pharmaceuticals position peaked at $51K in Q1 2016.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Ropes Wealth Advisors's 13F filing for Q4 2018, filed 8 Feb 2019.